XML 60 R41.htm IDEA: XBRL DOCUMENT v3.2.0.727
Equity Instruments - Summary of Stock-Based Compensation Expense (Detail) - USD ($)
9 Months Ended 12 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Jun. 30, 2014
Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expenses $ 750,000 $ 385,000 $ 500,000 $ 317,000
Luoxis Diagnostics [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Unrecognized expense at March 31, 2015     $ 1,129,000  
Weighted average remaining years to vest     2 years 2 months 23 days  
Vyrix Pharmaceuticals [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Unrecognized expense at March 31, 2015     $ 194,000  
Weighted average remaining years to vest     1 year 9 months 15 days  
Research and Development Expenses [Member] | Stock Options [Member] | Luoxis Diagnostics [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expenses 297,000 155,000 $ 206,000 203,000
Research and Development Expenses [Member] | Stock Options [Member] | Vyrix Pharmaceuticals [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expenses 26,000 29,000 38,000  
General and Administrative Expenses [Member] | Stock Options [Member] | Luoxis Diagnostics [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expenses 371,000 116,000 152,000 $ 114,000
General and Administrative Expenses [Member] | Stock Options [Member] | Vyrix Pharmaceuticals [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expenses $ 56,000 $ 85,000 $ 104,000